The company said operations at its facilities located at Plot Nos. 18 and 19, PHARMEZ Pharmaceutical Special Economic Zone, Village Matoda, Sarkhej Bawla, Ahmedabad, were suspended as a precautionary measure following waterlogging.
Piramal Pharma said all employees, including contract staff, at the affected facilities are safe.
ALSO READ | Piramal Pharma receives USFDA EIR for US facility; inspection closed with VAI
The company has initiated steps to assess the condition of the facilities and facilitate a safe and orderly resumption of operations. The extent of any impact on assets and operations is currently under evaluation.
Subject to improvement in weather conditions, operations are expected to gradually normalise over the next few days, the company said.
Piramal Pharma added that the assets at the affected facilities are adequately covered under the company’s insurance policies. The company said the affected facilities together account for less than 3% of its consolidated revenue.
It said it will provide further updates, including any material developments or financial implications, as appropriate.
ALSO READ | Piramal Pharma shares recover from lows, surge 3% after Co affirms FY26 guidance
In April this year, Piramal Pharma expects growth to pick up in the financial year 2026-27 (FY27) after a transitional 2025-26 (FY26), with momentum supported by improving demand in its contract development and manufacturing (CDMO) business and new product additions, Chairperson Nandini Piramal said.
She said FY26 was impacted by external factors, including macro volatility and product destocking.
Piramal said the outlook has improved with better demand indicators. “We expect biopharma funding has also gone up, and so we’ve seen an increase in RFPs as well as order inflows,” she said, adding that the company is exiting FY26 with stronger momentum.
She guided growth in the coming year. “We are guiding for growth around early to mid-teens… and EBITDA to possibly outpace revenue growth,” she said.
ALSO READ | Biosecure Act opens new CDMO opportunity for India, says Piramal Pharma chairperson
The CDMO segment is seeing improved activity, with US biotech funding rising sharply in the second half of FY26, leading to higher order visibility. The company said commercial product growth remained strong, even excluding the impact of a single large product.
Shares of Piramal Pharma Ltd ended at ₹181.65, up by ₹0.80, or 0.44%, on the BSE.
